elironrasib

AXP000028.1 · Targeted small molecule

Platform
small molecule
Targets
KRAS
Originator
Revolution Medicines
Sponsor
Revolution Medicines

Names

NameTypeSource
elironrasibpreferred name, INNcurator, ncit
RMC-6291codencit

Cross-references

NCI Thesaurus
C189824
Wikidata
Q140529143
FDA UNII
942KVV5CJP

Approvals

No regulatory approval recorded.

Clinical trials (4)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT07397338Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid TumorsRecruitingPhase 1/22026-01-302029-05370Advanced Solid Tumors; CRC; Colorectal Cancer (CRC); Metastatic Solid Tumors; NSCLC; Non-small Cell Lung Cancer (NSCLC)
NCT06162221Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLCRecruitingPhase 1/22024-01-182027-06616KRAS G12C-mutated Solid Tumors, Lung Cancer; KRAS, NRAS, HRAS-mutated NSCLC; Lung Cancer Stage IV, Advanced Solid Tumor, Cancer; Non-Small Cell Lung Cancer, NSCLC; RAS G12D-mutated NSCLC
NCT06128551Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid TumorsRecruitingPhase 1/22023-11-142028-12534Colorectal Cancer; Non-Small Cell Lung Cancer (NSCLC); Pancreatic Ductal Adenocarcinoma
NCT05462717Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid TumorsActive not recruitingPhase 12022-09-192027-03-31222Advanced Solid Tumor; Colorectal Cancer (CRC); Non-Small Cell Lung Cancer (NSCLC); Pancreatic Ductal Adenocarcinoma

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 40056080Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers.Journal of medicinal chemistry2025cited by trial NCT06128551
PMID 37590355Chemical remodeling of a cellular chaperone to target the active state of mutant KRAS.Science (New York, N.Y.)2023cited by trial NCT05462717

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 41165456RAS-GTP Inhibition Overcomes Acquired Resistance to KRASG12C Inhibitors Mediated by Oncogenic and Wild-Type RAS Activation in Non-Small Cell Lung Cancer.Cancer research2026name in abstract: elironrasib
PMID 41340466Activity of Direct KRAS(G12C) Inhibitors in Preclinical Models of Pediatric Cancer.Molecular cancer therapeutics2026name in abstract: RMC-6291
PMID 41405236"The RAS Dam Has Broken".Cancer discovery2026name in abstract: elironrasib
PMID 41670434Abrogation of Oncogenic RAS Signaling by a RAS(ON) Inhibitor Doublet Primes Immune-Refractory KRASG12C-Mutant NSCLC for Immune Checkpoint Blockade.Cancer discovery2026name in abstract: elironrasib
PMID 42457978Evolution of KRAS molecular glues: from allele-selective to Pan-RAS and protein-protein interaction modulators.Acta pharmacologica Sinica2026name in abstract: RMC-6291
PMID 42511798KRAS G12C-Targeted Therapy in Non-Small Cell Lung Cancer: From Resistant Salvage to Potential First-Line Backbone.International journal of molecular sciences2026name in abstract: RMC-6291
PMID 42841489Variant-selective and pan-RAS inhibitors enhance targeted agent activity in patient-derived multi-cell type tumor spheroids.Molecular cancer therapeutics2026name in abstract: elironrasib
PMID 42870846Activity and specificity of KRAS variants-directed Revolution Medicines Company (RMC) compounds for pleural effusion-derived non-small cell lung cancer cell lines.Translational lung cancer research2026name in abstract: elironrasib
PMID 42963543KRAS in pancreatic cancer: from molecular biology to transformative therapeutics.Journal of hematology & oncology2026name in abstract: elironrasib
PMID 42975930Rapid target engagement of KRAS G12C tricomplex inhibitor RO3903 overcomes resistance and drives durable tumor regression.Proceedings of the National Academy of Sciences of the United States of America2026name in abstract: elironrasib
PMID 42984346Variant-Selective and Pan-RAS Inhibitors Enhance Targeted Agent Activity in Patient-Derived Multi-cell-type Tumor Spheroids.Molecular cancer therapeutics2026name in abstract: elironrasib
PMID 39993169Discovery of Elironrasib (RMC-6291), a Potent and Orally Bioavailable, RAS(ON) G12C-Selective, Covalent Tricomplex Inhibitor for the Treatment of Patients with RAS G12C-Addicted Cancers.Journal of medicinal chemistry2025name in title: elironrasib
PMID 39215000RAS-ON inhibition overcomes clinical resistance to KRAS G12C-OFF covalent blockade.Nature communications2024name in abstract: RMC-6291

NIH grants

ProjectTitleOrganisationPIYearsLinked by
ZIABC011892Targeting RAS in Pediatric CancerDIVISION OF BASIC SCIENCES - NCIYOHE, MARIELLE2019–2025name in abstract: RMC-6291

Notes

KRAS G12C(ON) covalent tri-complex inhibitor. Wikidata QID not confirmed.

How to cite

elironrasib (AXP000028.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000028.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.